explore -WSS

explore

author：leisure time 2025-10-01 05:39:57 - browse：5

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： What should King Charles tell the public about his cancer?

WSS

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

To avoid data mishandling cases, universities eye AI and other tools

Pharma patents targeted by Biden in move to slash drug prices

FDA approves world's first CRISPR

After sickle

In diabetes hearing, Sanders takes on a new foe: food makers

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Activists slam private health insurers over coverage restrictions

Pfizer plans to depart BIO

Alkermes shareholders re

Leukemia patients are helped by Syndax's new type of therapy

Medical leaders decry Supreme Court decision on affirmative action

Why did Pfizer dish out millions for a Super Bowl ad?

Affirmative action in medical school literally saved lives

A disappointing year of Humira biosimilars

Affirmative action in medical school literally saved lives

The Readout: Gilead, Bernie Sanders, and other pharma news

focus

How digital tools helped lower hypertension in marginalized patients

Medicare Advantage proposed rates disappoint insurers

Robert F. Kennedy is pitching centrism on health, even on abortion

Leukemia patients are helped by Syndax's new type of therapy

Industry veterans launch new biotech VC with $310M

How digital tools helped lower hypertension in marginalized patients

focus

Wikipedia

leisure time

hotspot